Post-MI Baseline LDL Burden
Placeholder: baseline LDL is high right after an acute coronary event.
- 190 mg/dL: Baseline LDL (Placeholder value)
- <70 mg/dL: Guideline target (Placeholder value)
- Lipid-rich: Plaque core (Placeholder value)
- Thin/fragile: Cap status (Placeholder value)
Why baseline LDL matters
Placeholder: high LDL drives ongoing plaque lipid accumulation.
High-Intensity Statin Initiation
Placeholder: high-intensity statin therapy is started promptly.
- High-intensity: Statin class (Placeholder value)
- Atorva/Rosuva: Typical agents (Placeholder value)
- >50%: Expected LDL drop (Placeholder value)
- At discharge: Start timing (Placeholder value)
Why start high-intensity early
Placeholder: early high-dose therapy maximizes secondary prevention benefit.
LDL Reduction Toward Target
Placeholder: LDL declines sharply toward the guideline-recommended target.
- >50%: Target reduction (Placeholder value)
- ~4-6 wks: Time to effect (Placeholder value)
- <70 mg/dL: LDL at target (Placeholder value)
- Lipid panel: Monitoring (Placeholder value)
Dose-response of LDL lowering
Placeholder: greater LDL lowering associates with greater plaque benefit.
Fibrous Cap Stabilization
Placeholder: sustained LDL lowering thickens and stabilizes the fibrous cap.
- Increasing: Cap thickness (Placeholder value)
- Shrinking: Core size (Placeholder value)
- Decreasing: Inflammation (Placeholder value)
- IVUS/OCT: Imaging tool (Placeholder value)
Plaque regression mechanism
Placeholder: lipid efflux and reduced inflammation stabilize plaque.
Recurrent Event Risk Reduction
Placeholder: stabilized plaque and lower LDL reduce recurrent MI risk.
- ~30-45%: Relative risk ↓ (Placeholder value)
- 2 years: Time horizon (Placeholder value)
- Critical: Adherence (Placeholder value)
- Fewer MACE: Outcome (Placeholder value)
Long-term secondary prevention
Placeholder: durable therapy sustains lower recurrent event risk.
Placeholder: consistent high-intensity statin use is key to lasting benefit.